CN112798481A - 一种用于检测脂蛋白颗粒浓度的试剂及其使用方法 - Google Patents
一种用于检测脂蛋白颗粒浓度的试剂及其使用方法 Download PDFInfo
- Publication number
- CN112798481A CN112798481A CN202011160074.3A CN202011160074A CN112798481A CN 112798481 A CN112798481 A CN 112798481A CN 202011160074 A CN202011160074 A CN 202011160074A CN 112798481 A CN112798481 A CN 112798481A
- Authority
- CN
- China
- Prior art keywords
- concentration
- reagent
- density
- detecting
- buffer solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 title claims abstract description 62
- 102000004895 Lipoproteins Human genes 0.000 title claims abstract description 56
- 108090001030 Lipoproteins Proteins 0.000 title claims abstract description 56
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 39
- 238000001514 detection method Methods 0.000 claims abstract description 37
- 239000007853 buffer solution Substances 0.000 claims abstract description 21
- 239000000243 solution Substances 0.000 claims abstract description 15
- 239000000126 substance Substances 0.000 claims abstract description 15
- 239000003085 diluting agent Substances 0.000 claims abstract description 13
- 239000000523 sample Substances 0.000 claims description 43
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
- 239000011780 sodium chloride Substances 0.000 claims description 16
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 14
- 238000005119 centrifugation Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 8
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 239000012470 diluted sample Substances 0.000 claims description 7
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 5
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 2
- 239000008055 phosphate buffer solution Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 16
- 235000012000 cholesterol Nutrition 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 2
- 239000000872 buffer Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 108010004103 Chylomicrons Proteins 0.000 description 3
- 108010046315 IDL Lipoproteins Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 208000010152 Huntington disease-like 3 Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001225 nuclear magnetic resonance method Methods 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/06—Investigating concentration of particle suspensions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/06—Investigating concentration of particle suspensions
- G01N15/075—Investigating concentration of particle suspensions by optical means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N2015/0042—Investigating dispersion of solids
- G01N2015/0053—Investigating dispersion of solids in liquids, e.g. trouble
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (10)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011160074.3A CN112798481B (zh) | 2020-10-27 | 2020-10-27 | 一种用于检测脂蛋白颗粒浓度的试剂及其使用方法 |
US18/029,110 US20230366895A1 (en) | 2020-10-27 | 2021-02-04 | Reagent for detecting lipoprotein particle concentration and using method thereof |
PCT/CN2021/075263 WO2022088550A1 (zh) | 2020-10-27 | 2021-02-04 | 一种用于检测脂蛋白颗粒浓度的试剂及其使用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011160074.3A CN112798481B (zh) | 2020-10-27 | 2020-10-27 | 一种用于检测脂蛋白颗粒浓度的试剂及其使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112798481A true CN112798481A (zh) | 2021-05-14 |
CN112798481B CN112798481B (zh) | 2022-02-18 |
Family
ID=75806195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011160074.3A Active CN112798481B (zh) | 2020-10-27 | 2020-10-27 | 一种用于检测脂蛋白颗粒浓度的试剂及其使用方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230366895A1 (zh) |
CN (1) | CN112798481B (zh) |
WO (1) | WO2022088550A1 (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103454191A (zh) * | 2003-07-02 | 2013-12-18 | 泰尔茂比司特公司 | 用于利用预测数据分析算法控制血液处理离心机的方法 |
WO2013188879A1 (en) * | 2012-06-16 | 2013-12-19 | Atherotech, Inc. | Measurement of serum lipoproteins |
US20140049775A1 (en) * | 2012-06-16 | 2014-02-20 | Atherotech, Inc. | Measurement of serum lipoproteins |
CN103833840A (zh) * | 2012-11-27 | 2014-06-04 | 上海复星医药(集团)股份有限公司 | 一种从人血浆中提取高密度脂蛋白及分离纯化载脂蛋白apoA-I的方法 |
CN105137070A (zh) * | 2015-08-03 | 2015-12-09 | 复旦大学附属中山医院 | 改良凝胶电泳检测血清前β1高密度脂蛋白的方法和应用 |
CN107287277A (zh) * | 2017-06-23 | 2017-10-24 | 美康生物科技股份有限公司 | 小而密低密度脂蛋白胆固醇检测试剂盒 |
CN110108673A (zh) * | 2019-04-23 | 2019-08-09 | 江西维瑞生物科技有限公司 | 用于同时检测脂蛋白亚组分胆固醇和脂蛋白颗粒浓度的检测系统 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE525635T1 (de) * | 2001-11-13 | 2011-10-15 | Univ California | Ionenmobilitätsanalyse biologischer partikel |
WO2007133593A2 (en) * | 2006-05-10 | 2007-11-22 | Liposcience, Inc. | Methods, systems and computer programs for assessing chd risk using weighted hdl particle number measurements |
US7521248B2 (en) * | 2007-04-20 | 2009-04-21 | Atherotech, Inc. | Apo B measurement system and method |
CN102018699B (zh) * | 2010-12-14 | 2014-03-26 | 中山大学 | Xyloketal B在制备调节血脂水平药物中的应用 |
CN103149370B (zh) * | 2013-02-27 | 2015-02-18 | 宁波美康生物科技股份有限公司 | 脂蛋白(a)检测试剂盒 |
CN104597252A (zh) * | 2015-01-23 | 2015-05-06 | 浙江卓运生物科技有限公司 | 一种人血清氧化低密度脂蛋白的免疫比浊检测试剂盒 |
CN107561297B (zh) * | 2017-08-25 | 2019-12-10 | 宁波美康盛德医学检验所有限公司 | 用于血脂分型检测的试剂 |
-
2020
- 2020-10-27 CN CN202011160074.3A patent/CN112798481B/zh active Active
-
2021
- 2021-02-04 WO PCT/CN2021/075263 patent/WO2022088550A1/zh active Application Filing
- 2021-02-04 US US18/029,110 patent/US20230366895A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103454191A (zh) * | 2003-07-02 | 2013-12-18 | 泰尔茂比司特公司 | 用于利用预测数据分析算法控制血液处理离心机的方法 |
WO2013188879A1 (en) * | 2012-06-16 | 2013-12-19 | Atherotech, Inc. | Measurement of serum lipoproteins |
US20140049775A1 (en) * | 2012-06-16 | 2014-02-20 | Atherotech, Inc. | Measurement of serum lipoproteins |
CN103833840A (zh) * | 2012-11-27 | 2014-06-04 | 上海复星医药(集团)股份有限公司 | 一种从人血浆中提取高密度脂蛋白及分离纯化载脂蛋白apoA-I的方法 |
CN105137070A (zh) * | 2015-08-03 | 2015-12-09 | 复旦大学附属中山医院 | 改良凝胶电泳检测血清前β1高密度脂蛋白的方法和应用 |
CN107287277A (zh) * | 2017-06-23 | 2017-10-24 | 美康生物科技股份有限公司 | 小而密低密度脂蛋白胆固醇检测试剂盒 |
CN110108673A (zh) * | 2019-04-23 | 2019-08-09 | 江西维瑞生物科技有限公司 | 用于同时检测脂蛋白亚组分胆固醇和脂蛋白颗粒浓度的检测系统 |
Also Published As
Publication number | Publication date |
---|---|
WO2022088550A1 (zh) | 2022-05-05 |
CN112798481B (zh) | 2022-02-18 |
US20230366895A1 (en) | 2023-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cadamuro et al. | Influence of centrifugation conditions on the results of 77 routine clinical chemistry analytes using standard vacuum blood collection tubes and the new BD-Barricor tubes | |
JP2799835B2 (ja) | コレステロールの定量方法 | |
Assmann et al. | Quantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. | |
JP3193634B2 (ja) | Ldlコレステロールの定量方法 | |
CN105296597B (zh) | 检测高密度脂蛋白胆固醇含量的试剂盒 | |
CN106383116A (zh) | 一种检测高密度脂蛋白胆固醇的试剂盒 | |
Castro-Castro et al. | Removing lipemia in serum/plasma samples: a multicenter study | |
CN107561297B (zh) | 用于血脂分型检测的试剂 | |
Nauck et al. | Homogeneous assay for direct determination of high-density lipoprotein cholesterol evaluated | |
Lippi | Interference studies: focus on blood cell lysates preparation and testing | |
CN113156018B (zh) | 一种肝胆疾病诊断模型的建立方法及诊断系统 | |
DK159840B (da) | Reagens til bestemmelse af low density lipoproteiner (ldl) | |
CN109609595A (zh) | 一种小而密低密度脂蛋白胆固醇测定试剂盒及其应用 | |
JP3104988B2 (ja) | 全血中のhdlの分離方法 | |
CN113470814B (zh) | 检测alr、nlr、plr和anri的物质在预测血管侵犯发生风险中的应用 | |
CN112798481B (zh) | 一种用于检测脂蛋白颗粒浓度的试剂及其使用方法 | |
CN116539880B (zh) | 检测代谢物和/或组织蛋白的试剂在制备痛风性关节炎筛查试剂盒中的用途 | |
Okada et al. | Direct measurement of HDL cholesterol: method eliminating apolipoprotein E‐rich particles | |
EP1164376B1 (en) | Method for quantitating cholesterol | |
US9675283B2 (en) | Methods for classifying pleural fluid | |
Yamaguchi | Determination of high-density lipoprotein phospholipids in serum. | |
JP4588835B2 (ja) | リポ蛋白分離分析法、リポ蛋白分離分析装置、およびリポ蛋白分離分析システム | |
WO2002006832A1 (fr) | Moyen d'examen pour la nephropathie | |
US20120282631A1 (en) | Method for diagnosis non-small-cell-lung-carcinoma (nsclc) and classification of its subtypes with different combinations of 6 protein biomarkers | |
WO2008021865A2 (en) | Method for analyzing blood for lipoprotein components |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210514 Assignee: Zhengzhou Meikang Shengde medical laboratory Co.,Ltd. Assignor: MEDICAL SYSTEM BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2023980042028 Denomination of invention: A reagent for detecting the concentration of lipoprotein particles and its usage method Granted publication date: 20220218 License type: Common License Record date: 20230919 Application publication date: 20210514 Assignee: Xinyu Meikang Shengde medical laboratory Co.,Ltd. Assignor: MEDICAL SYSTEM BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2023980042025 Denomination of invention: A reagent for detecting the concentration of lipoprotein particles and its usage method Granted publication date: 20220218 License type: Common License Record date: 20230919 Application publication date: 20210514 Assignee: NINGBO MEDICALSYSTEM CLINICAL LABORATORIES Co.,Ltd. Assignor: MEDICAL SYSTEM BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2023980042024 Denomination of invention: A reagent for detecting the concentration of lipoprotein particles and its usage method Granted publication date: 20220218 License type: Common License Record date: 20230919 |